Skip to content

Multi-central, perspective comparison of different lymph node dissection strategy on the survival of early stage, grand glass non-small cell lung cancer patients

Multi-central, perspective comparison of different lymph node dissection strategy on the survival of early stage, grand glass non-small cell lung cancer patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022976
Enrollment
Unknown
Registered
2019-05-06
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

systematic lymoh node dissection group:systematic lymoh node dissection
lobe specific lymoh node dissection group:lobe specific lymoh node dissection

Sponsors

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. clinical non-small cell lung cancer; 2. single pulmonary nodule =2cm; 3. pre-operative evaluation found no lymph node metastasis or distant metastasis; 4. plan to receive VATS anatoical lung resection plun lymph node dissection; 5. aged 20-70 years.

Exclusion criteria

Exclusion criteria: 1. active bacteria or fungal infection; 2. use of anticoagulants within one month; 3. pulmonary diseases including interstitial lung disease, lung fibrosis, emphysema pulmonum; 4. mental disorders; 5. untrolled hypertention, DM; 6. angina, myocardial infarction and heart failure within 6 months; 7. history of lung TB; 8. history of Trauma of the chest; 9. systematic glucocorticoid treatment; 10. significant abnormality of coagulation function; 11. patients with poor compliance; 12. patients who are thought to be unsuitable to participate.

Design outcomes

Primary

MeasureTime frame
Diseases free survival;

Secondary

MeasureTime frame
overall survival;post operative complication;

Countries

China

Contacts

Public ContactJun Zhao

Cancer Hospital, Chinese Academy of Medical Sciences

drzhaojun@126.com+86 13601025252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026